UN Wildlife Conference Ends with Protection for 500 Species 

This photo provided by the Wildlife Conservation Society shows a reticulated glass frog at the Bronx Zoo in the Bronx borough of New York, April 10, 2017. (Wildlife Conservation Society via AP)
This photo provided by the Wildlife Conservation Society shows a reticulated glass frog at the Bronx Zoo in the Bronx borough of New York, April 10, 2017. (Wildlife Conservation Society via AP)
TT

UN Wildlife Conference Ends with Protection for 500 Species 

This photo provided by the Wildlife Conservation Society shows a reticulated glass frog at the Bronx Zoo in the Bronx borough of New York, April 10, 2017. (Wildlife Conservation Society via AP)
This photo provided by the Wildlife Conservation Society shows a reticulated glass frog at the Bronx Zoo in the Bronx borough of New York, April 10, 2017. (Wildlife Conservation Society via AP)

An international conference on trade in endangered species ended Friday in Panama, with protections established for over 500 species. 

The measures were approved by the Convention on International Trade in Endangered Species of Wild Fauna and Flora, known by its initials as CITES. 

The conference agreed to tighten trade regulations on sharks targeted by the fin trade and tiny frogs with translucent skin. 

Global shark populations are declining, with annual deaths due to fisheries reaching about 100 million. The sharks are sought mostly for their fins, which are used in shark fin soup, a popular delicacy in China and elsewhere in Asia. 

Over two weeks, the 184-nation gathering sought to combat trade in species facing extinction. 

The international wildlife trade treaty, which was adopted 49 years ago in Washington, DC, has been praised for helping stem the illegal and unsustainable trade in ivory and rhino horns as well as in whales and sea turtles. 

The translucent or “glass” frogs have been hit hard by habitat loss, diseases and their popularity in the pet trade, said Joaquín de la Torre, the international director for the International Fund for Animal Welfare, IFAW. 

“We have been waiting for this for three years,” De la Torre said of the protections. “They are very charismatic species.” 

The conference also voted to restrict trade in South American fresh-water turtles known as Matamata, whose spikey, pre-historic appearance has made them popular among collectors. 

CITES approved 46 of the 52 proposals presented, including restrictions on dozens of tree species. 

Fans of hippos, found in more than three dozen African countries and regulars in nature documentaries, had hoped the convention would ban commercial trade, but that proposal was not approved. 

The proposal to ban the hippo trade was opposed by the European Union, some African countries and several conservation groups, who argue many countries have healthy hippo populations and that trade isn’t a factor in their decline. 



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”